Form 4 filing overview: On 07/02/2025, Incyte Corp. (INCY) Principal Accounting Officer Tray Thomas satisfied tax-withholding obligations related to previously granted restricted stock units (RSUs).
- Transaction code F denotes shares withheld by the issuer for taxes—not an open-market sale.
- Shares withheld: 897 common shares at an implied price of $68.17.
- Post-transaction holdings: 21,106 common shares, of which 13,456 are unvested RSUs.
No derivative securities were exercised or disposed of. The filing represents an administrative, non-discretionary transaction and does not signal a change in the executive’s investment thesis or company fundamentals.
Form 4 filing overview – Incyte Corp. (INCY)
Executive Vice President & Chief Medical Officer Dr. Steven H. Stein reported an internal share withholding transaction dated 07/02/2025. The Code “F” event reflects 12,714 common shares automatically withheld by the issuer to cover tax obligations arising from the settlement of previously granted restricted stock units (RSUs) or earned performance shares. The withholding price was $68.17 per share.
After the transaction, Dr. Stein directly owns 112,418 common shares. This figure includes 94,907 unvested RSUs/performance shares that remain subject to future vesting conditions. No open-market purchases or sales and no derivative security activity were reported.
The filing represents a routine administrative tax-related disposition and does not signal a discretionary sale. There are no indications of broader strategic changes, earnings data, or material corporate developments within this document.